Amphastar Pharmaceuticals, Inc. (AMPH)

NASDAQ: AMPH · IEX Real-Time Price · USD
43.91
+0.39 (0.90%)
Mar 28, 2024, 4:00 PM EDT - Market closed
0.90%
Market Cap 2.13B
Revenue (ttm) 644.40M
Net Income (ttm) 137.55M
Shares Out 48.10M
EPS (ttm) 2.60
PE Ratio 16.89
Forward PE 11.61
Dividend n/a
Ex-Dividend Date n/a
Volume 453,248
Open 43.76
Previous Close 43.52
Day's Range 43.76 - 44.83
52-Week Range 35.62 - 67.66
Beta 0.85
Analysts Buy
Price Target 59.25 (+34.94%)
Earnings Date May 7, 2024

About AMPH

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection eme... [Read more]

Sector Healthcare
IPO Date Jun 25, 2014
Employees 1,761
Stock Exchange NASDAQ
Ticker Symbol AMPH
Full Company Profile

Financial Performance

In 2023, AMPH's revenue was $644.40 million, an increase of 29.14% compared to the previous year's $498.99 million. Earnings were $137.55 million, an increase of 50.51%.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is $59.25, which is an increase of 34.94% from the latest price.

Price Target
$59.25
(34.94% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operation...

22 days ago - Accesswire

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023

Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" o...

4 weeks ago - Accesswire

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024

RANCHO CUCAMONGA, CA / ACCESSWIRE / February 20, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31, ...

5 weeks ago - Accesswire

Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at t...

3 months ago - Accesswire

Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 20, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will p...

4 months ago - Accesswire

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi EVP of Corp. Administration, will parti...

5 months ago - Accesswire

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023

Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" o...

5 months ago - Accesswire

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2023 ended September 30, 2...

5 months ago - Accesswire

Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 13, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced the pricing of $300.0 million aggregate principal amount of 2.00% c...

7 months ago - Accesswire

Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 11, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced that it intends to offer, subject to market conditions and other fa...

7 months ago - Accesswire

Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operati...

7 months ago - Accesswire

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023

Reports Net Revenues of $145.7 Million for the Three Months Ended June 30, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "...

8 months ago - Accesswire

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 2, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2023 ended June 30, 2023, a...

8 months ago - Accesswire

Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly

RANCHO CUCAMONGA, CA / ACCESSWIRE / June 30, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today announced that it has completed the previously announced acquisit...

9 months ago - Accesswire

Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner SVP of Corp. Communication, will participate in ...

10 months ago - Accesswire

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023

Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Co...

11 months ago - Accesswire

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 3, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2023 ended March 31, 2023, afte...

11 months ago - Accesswire

Eli Lilly to sell hypoglycemia treatment for up to $1.1 billion in cash and milestone payments to Amphastar

Shares of Eli Lilly & Co. LLY gained 0.5% in premarket trading Monday, after the drugmaker announced an agreement to sell its hypoglycemia treatment for people with diabetes Baqsimi to Amphastar Pharm...

Other symbols: LLY
1 year ago - Market Watch

Lilly to Divest BAQSIMI to Amphastar

Lilly focused on delivering the company's unprecedented pipeline of next-generation medicines to help patients Amphastar is the ideal company to continue Lilly's mission to help more people benefit fr...

Other symbols: LLY
1 year ago - PRNewsWire

Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 24, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will provide a Business update and hold a Conference call today, Monday, A...

1 year ago - Accesswire

Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 12, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Jacob Liawatidewi, EVP of Corporate Administration, Tony Marrs...

1 year ago - Accesswire

Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced that the U.S. Food and Drug Administration ("FDA") has grante...

1 year ago - Accesswire

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022

Reports Net Revenues of $135.0 Million for the Three Months Ended December 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" o...

1 year ago - Accesswire

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023

RANCHO CUCAMONGA, CA / ACCESSWIRE / February 22, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2022 ended December 31, ...

1 year ago - Accesswire

Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Cl...

1 year ago - Accesswire